Investors may be asking whether Moderna's current share price reflects its underlying worth, or if the market is mispricing ...

Moderna's full pipeline may fuel long-term growth.

They aren't just "pandemic stocks." ...

European Medicines Agency approves Moderna's mRNA flu vaccine with strong efficacy in older adults. US FDA initially declines ...

In the latest trading session, Moderna (MRNA) closed at $49.20, marking a -1.66% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.11%. On the other hand, ...

COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver ...

U.S. large-cap healthcare stocks have delivered modest year-to-date gains in 2026, holding steady into March amid its ...

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...

Moderna (MRNA) stock jumped more than 6% on Wednesday after the US Food and Drug Administration agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to reject ...

Signed Memorandum of Understanding supports “Plan Mexico,” Mexico’s strategic initiative to build a local mRNA ecosystem and strengthen health security Strategic agreement will enable access to ...